# To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT07454187** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Hangzhou Sumgen Biotech Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** SG2918

## Key facts

- **NCT ID:** NCT07454187
- **Lead sponsor:** Hangzhou Sumgen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-14
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07454187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07454187, "To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07454187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*